This site is currently not optimized for mobile devices. For the best user experience, please access the site via a device with a wider screen such as a desktop or laptop.

For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Once enabled, click here to view the site.

singup link button why should I sign up?
Login as Volunteer Login as Study team member
OR

Studies you may be eligible for. 14

Based on the information you provided, we found the following studies.

  • A Phase 1, Open-label, Dose Escalation, Safety and Tolerability Study of Investigational Drug INCB054828 in Subjects with Advanced Malignancies Study goals: determine dose that is safe and tolerable in people with advanced cancer and select the doses that will be studied further; see how INCB054828 acts on and in the body; see effect INCB054828 has on the growth of your cancer; see action of INCB054828 in the body over a period of time This study is researching all of the following topics: Bladder cancer Cervical cancer Colon Cancer ( Malignant tumor of colon ) Colorectal / Colon / Rectal cancer Kidney Cancer ( Malignant tumor of kidney ) Lung cancer Multiple myeloma Prostate cancer This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A Phase 2b, Open-Label, Single-Arm Study of investigational drug Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies This study will examine the effects of selinexor on your cancer and on your body, including any side effects you may have.You may be eligible to participate because you have been diagnosed with multiple myeloma, your previous treatments have not been successful, and your cancer is progressing. This study is researching all of the following topics: Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • An Open-Label, Single Arm, Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone and investigational drug Elotuzumab in Newly Diagnosed Multiple Myeloma This research study is testing the safety and effectiveness of an investigational drug (elotuzumab) in combination with lenalidomide, bortezomib, and dexamethasone to learn more about the side effects of this regimen and whether it is effective in newly diagnosed multiple myeloma. This study is researching all of the following topics: Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • PH Ib STUDY OF THE SAFETY AND PHARMACOKINETICS OF MPDL3280A (ANTI-PD-L1 ANTIBODY) ALONE OR IN COMBINATION WITH LENALIDOMIDE IN SUBJECTS WITH MULTIPLE MYELOMA (RELAPSED AND POST ASCT) The purpose of this study is to test the safety of the combination of an experimental drug called MPDL3280A and lenalidomide (Revlimid®) at different dose levels and to find out what effects, good or bad, the combination of these drugs has on you. This study is researching all of the following topics: Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma (SMM) The purpose of this study is to find the dose of investigational drug Daratumumab that would be best to use in future studies for the treatment of SMM. The effects on SMM as well as any side effects will be explored. This study is researching all of the following topics: Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Ph I Stdy Investigating Safety/Pharmacokinetics/Pharmacodynamics/Immunogenicity/Clinical Activity of GSK2857916 in Subjects with Myeloma/Other Advanced Hematologic Malignancies Exprssng BCMA Study goal: test experimental drug GSK2857916 in patients with multiple myeloma or other blood cancers.Part 1 Dose Escalation: find highest dose that does not cause serious side effects;Part 2 Dose Expansion: test safety, how it behaves in human body, and whether it works in treating your condition. This study is researching all of the following topics: CLL ( Chronic lymphocytic leukemia) Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase I Study of an Oncofetal Antigen ("OFA") Multi-Peptide Immunotherapy ("BB-MPI-03"), a vaccine, in Subjects with Hematologic Cancer (BB-MPI-03-Hem-01) Study purpose: determine the highest tolerable dose or optimal biologic dose of peptides in the vaccine that can be given, how it affects your immune system (the system your body uses to fight cancer, infections and ¿foreign bodies¿) and whether it causes your cancer to shrink or remain stable. This study is researching all of the following topics: AML ( Acute myeloid leukemia ) MDS ( Myelodysplastic syndrome ) Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase 2 Multicenter Study of Anti-Programmed-Death-1 [anti-PD-1] during Lymphopenic State After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplant [HDT/ASCT] for Multiple Myeloma This study will test if additional post-transplant treatment (every 3 weeks for 6 months) with anti-PD1 can lead to a safe and more effective treatment approach for patients with MM, compared with a standard transplant alone. This study is researching all of the following topics: Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • Less than 75 years old
    • More than 18 years old
  • Phase 1 Dose Escalation w/Two Disease Specific Expansions, Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Hematologic Malignancies Study Purpose: test the safety of APTO-253; find the maximum dose of APTO-253 which can be tolerated when given two times a week; find out what effects, good and/or bad, this treatment has on you and your cancer and how APTO-253 may work in the body and your body's ability to get rid of APTO-253. This study is researching all of the following topics: ALL ( Acute lymphoblastic leukemia ) AML ( Acute myeloid leukemia ) Hodgkin's lymphoma Leukemia Lymphoma MDS ( Myelodysplastic syndrome ) Multiple myeloma Non-Hodgkin's lymphoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase I Study of Experimental Combination of Experimental drug Selinexor with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Study goals: find the safest dose and side effects of Selinexor and carfilzomib in combination with dexamethasone in people with multiple myeloma that has not responded to prior treatments, including carfilzomib alone; and learn how well the combination of drugs works against multiple myeloma. This study is researching all of the following topics: Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
Showing 1-10 of 14 studies
Show more studies